NCT07673861Recruiting
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease). The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK). One hundred patients will be recruited, with 20 from each of the following cancer types: * Non-small cell lung cancer * Gastrointestinal stromal tumours * Colorectal cancer * Biliary tract cancer * Ovarian cancer. Patients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden. Patients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by: * Aiding the identification of a genomically-matched standard of care therapy * Aiding the identification of a genomically-matched clinical trial (based in the UK) * Offering additional prognostic information not otherwise available through standard of care testing * Negating the need for a tissue biopsy.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 19 Nov 2025
- Start date
- 23 May 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Royal Marsden NHS Foundation Trust
- NCT number
- NCT07673861
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 23 May 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- All cohorts:
- Medically unstable to commit to sampling required for the study
- ECOG performance status ≥3
Who the study is looking for
- All cohorts:
- Age ≥18 years old
- Ability to provide written informed consent
- Presence of metastatic or unresectable disease
- Being reviewed and treated through medical oncology service at Royal Marsden Hospital
- Cohort 1: Locally Advanced/Metastatic NSCLC
- Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND
- Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
- Cohort 2: Locally Advanced/Metastatic GIST
- Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND
- Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent
- Cohort 3: Metastatic Colorectal Cancer
- Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND
- If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent
- If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent
- Cohort 4: Locally Advanced/Metastatic BTC
- Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency \[dMMR\]), AND
- Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent
- Cohort 5: Advanced/Metastatic ovarian cancer
- Diagnosis of advanced/metastatic high-grade ovarian cancer, AND
- Known BRCA status, AND
- Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Marsden NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.